UroToday

SNMMI 2026: Does Early 177Lu-PSMA-617 SPECT/CT Improve Prognostic Assessment Beyond Baseline PSMA PET in mCRPC?

The 2026 SNMMI annual meeting featured a genitourinary radiotherapeutics session and a presentation by Dr. Yalda Nikanpour ...
ascopubs.org

[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients.

Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...
UroToday

SNMMI 2026: Predicting Early PSA Response to 177Lu-PSMA Therapy using Baseline PET Imaging Biomarkers and Cycle 1 Dosimetry

Higher baseline PET SUVmean and cycle 1 whole body tumor volume absorbed dose are associated with a more favorable PSA response following early cycles of 177 Lu-PSMA, as well as after therapy ...
Physics World

Advances in nuclear medicine technology reduce radiation exposure and shorten scan times

Lowering the dose: PET images reconstructed with CT-free techniques (left two columns) and with the use of CT images (centre column). The right two columns show difference images between attenuation ...